Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAN-1805
- Development stage
- Preclinical
- Lead developer
- Zedman
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
TAN-1805 is a small molecule aryl hydrocarbon receptor (AhR) modulator developed by Zedman Biopharma for the treatment of allergic rhinitis. Administered as an intranasal spray, the drug targets the AhR, a ligand-activated transcription factor involved in immune regulation and the maintenance of mucosal barrier integrity. By modulating AhR activity, TAN-1805 is intended to alleviate the inflammatory symptoms associated with allergic rhinitis. The program is currently in the Investigational New Drug (IND) stage of development.
- Other names
- TAN-1805 鼻喷剂TAN-1805 Nasal SprayTAN1805 Nasal SprayTAN 1805 Nasal Spray
02
Targets
AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on TAN-1805.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAN-1805.